|
||||||||||||||||||||||
|
|
Alternate Title Phase II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Disease or Cancer
Special Category: NIH Clinical Center trial Trial Description Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, before a donor stem cell transplant helps stop the growth of abnormal cells and cancer. It also stops the patient’s immune system from rejecting the donor’s stem cells. The donated stem cells may replace the patient’s immune system and help destroy any remaining abnormal or cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can make an immune response against the body’s normal cells. Giving antithymocyte globulin before transplant and cyclosporine after transplant may stop this from happening. This phase II trial is studying how well giving chemotherapy followed by a donor peripheral stem cell transplant works in treating patients with hematologic disease or hematologic cancer. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will receive a 1-hour infusion of cyclophosphamide once a day for 2 days followed by an infusion of fludarabine once a day for 5 days. Some patients will also receive an infusion of antithymocyte globulin once a day for 4 days. Patients will then undergo a donor peripheral stem cell transplant. They will receive cyclosporine beginning 4 days before the transplant and continuing for approximately 3½ months. Patients will be evaluated at 3 and 6 months, every 6 months for 2½ years, and once a year for 5 years. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations National Heart, Lung, and Blood Institute
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |